Revvity Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
yesterday. I think a good place to kick it off, just a quick look back at the analyst day last week. Maybe just highlight a couple of the key themes, takeaways, and how we should be thinking about obviously the LRP. You reiterated, maybe just talk a little bit about some of the takeaways.
Thank you, Tycho. Good morning. It is good to be here. The analyst day, it was a good opportunity for us to sort of reiterate what our long-range plan is and what the puts and takes have been. Since the last time we did it was more of an introduction to what Revvity is, as we were creating it and forming it. This was a good opportunity also to do a bit of a deeper dive onto the life sciences side, and that is where we spend most of the time.
Especially as we are looking at with the advent of new technology and AI and the impact it is having on our sector, we used the opportunity to do a deeper dive onto the Signals Software business, and also the sort of infinity loop model that we all are looking at as drug candidates come out of in silico, where with the Signals Software platform, we are very well positioned to be able to help researchers design molecules. Then as it moves into the wet lab side, with our software, with our reagents, with our instruments portfolio, to be able to have an impact on how we can help researchers throughout the continuum of drug development. So, it was a really good opportunity to do that.
We also went a bit deeper onto the Signals and the research side, where Craig Monell and David Gosalvez sort of tag-teamed into how our portfolio touches customers and researchers throughout the point of drug discovery and development, and the impact our portfolio has on that. Then Max ended up concluding with our LRP. So, it was a good day. Despite certain technology and logistics issues, it ended up with a pretty good attendance.
Great. We are certainly going to jump into some of the themes, AI in particular, in a minute. But maybe before we do that, just the initial 2027 framing, 6% core growth, 4% underlying market growth. Maybe just talk about the gives and takes, frankly, of both of those. What could be better for the market? What could be better for you?
Yeah. I mean, two things. One, the LRP didn't change from what we had before. So, our assumption is the market would grow around 400-600 basis points, and in that, we would be 200 basis points above market. So, 6%-8% was the range that we had earlier, and that's what we reiterated. There were minor puts and takes between the segments, with the software going up a bit on the life sciences side, and on the diagnostic side, immunodiagnostics coming down a smidge, and reproductive health going up a smidge. So, there were minor puts and takes, but overall, it was more of a reiteration of our long-range plan.
More importantly, there were two things that, as Max pointed out, one, it did not include any upside that we would see from AI, and the second aspect was it sort of did not include any capital deployment component that would impact that. So, that is sort of a gist of what we presented.
Are those the biggest swing factors as you think about 2027?
I think as we look into 2027, obviously, AI is going to have an impact, and it has already started showing, as we've talked about on the platform side. But just given where that journey is, and we are starting to see that obviously for 2027, we gave some considerations on what 2027 would look like, but we've got the next, I would say, eight to 10 weeks to be able to further solidify that and come out with what it will look like, specifically at the 4Q call.
One of the areas, obviously, that's improved are reagents. You're up high single digit third quarter. You're still calling for mid-single digit growth in the fourth quarter on reagents, despite some of the timing of the bulk orders. I guess, just thinking a little bit further ahead, how should we think about the durability of that into 2027 on the reagent side?
Tycho, as you look at our reagent side of the business, it has performed well, and it has been the differentiating portion of our portfolio, even during when the market downturn was ongoing. And we've started, obviously, starting to see the uplift coming out of that. From the perspective of as we are seeing the market turn around, typically as we do, the first investment goes into the CapEx side of the business, and that we've clearly started seeing with our orders outpacing revenue today. As this moves forward, we will continue to see the reagents starting to see a beneficial impact of that. Once these instruments are installed and tested and validated, that's when they go into full use. It definitely is going to have an impact on the reagent side of the business.
You're kind of outgrowing the market here on the reagent side, so I want to give you an opportunity to maybe talk about some of the initiatives that you have, 24-hour delivery, customer engagement, value-based pricing. Just talk a little bit about whether there's a share gain element here as well.
I think there are two components to it. As we look at it on the reagent side, we talked through it on our investor day. There is the RUO antibodies, and then there is the research reagents. Both of them complement each other. On the RUO antibody side and on the research side, the focus for us is that how are we on time delivery within 24 hours, 95% of our reagents get to our customers. Quality, the amount of work that we are involved in with research and their lab bench prior to. As they start using these antibodies in the design of the epitopes that they are going to require and what is needed. It has been an historic engagement over a period of time, especially on the BioLegend side of it.
As we move onto the research reagent side of the business, those are very sticky, and they get onto programs for validation. Every program that we get on, they are a multi-year program. I think that is the benefit we are seeing, and especially with the advent of new molecules, GLP-1 is one that we have talked about. As we get into those validation protocols, the stickiness of them remain on for a long period of time. I think that is where we see some of the competitive edge and advantage with the research reagent side of the portfolio.
You mentioned instruments a minute ago, mid-single digit in the third quarter, you are talking about high single digit in the fourth quarter, so an acceleration here. I guess beyond high-content screening, which we will talk about in a minute, just talk a little bit about the other platforms that are contributing.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
